VAVictor Asua

Victor Asua

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victor Asua has a total of 174 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Temporal organization of the Plasmodium falciparum transcriptome prioritises genetic polymorphisms associated with artemisinin response

    by Andrew Walakira, Ronald Galiwango, Brenda Namugamba, Shahiid Kiyaga, Kevin Cissy Nabukeera, Syrus Semawule, Edith Nabukenya, Joseph Nyanzi, Martin Okitwi, Stephen Orena, et al.

    Artemisinin-based combination therapies (ACTs) have substantially reduced the global burden of malaria, but the emergence and spread of artemisinin partial resistance (ART-R) threatens these gains. Although mutations in Plasmodium falciparum kelch13 (pfk13) are established mediators of ART-R, they do not fully explain variation in parasite responses, highlighting the need for complementary markers. We integrated six independent intra-erythrocytic developmental cycle (IDC) transcriptomic datasets by harmonic regression and random-effects meta-analysis, followed by network analyses, protein structural modelling, population genomics and ex vivo dihydroartemisinin susceptibility data, to identify candidate P. falciparum polymorphisms associated with artemisinin response. The meta-analysis identified 2,842 of 5,292 genes as significantly rhythmic across the 48-hour IDC, including those encoding PfK13 and PfMDR1. Integration with whole-genome sequences of Ugandan field isolates prioritized 13 nonsynonymous variants across 10 genes, encoding PfAP2-G, PfPX1, PfACS7, PfACS1a, PfRESA3, PfDRPC and PfA8IJP together with three proteins of unknown function, all transcriptionally co-timed with pfk13. Polymorphisms in pfpx1 have independently been implicated in artemisinin susceptibility, consistent with our prioritization. These candidates are potential complementary mediators of artemisinin response. Beyond them, the pipeline itself is transferable to other resistance phenotypes and periodic transcriptional programmes.

  • Open Access

    Whole-genome characterization of Plasmodium falciparum population structure and drug resistance across Uganda and neighboring countries

    by Shahiid Kiyaga, Monica Mbabazi, Thomas Katairo, Victor Asua, Francis D. Semakuba, Bienvenu Nsengimaana, Stephen Tukwasibwe, Innocent Wiringilimaana, Jackie Nakasaanya, Jerry Mulondo, et al.

    Uganda has one of the world’s highest malaria burdens, but parasite population structure and connectivity have not been characterized nationally with whole-genome data. We analyzed 249 monoclonal Plasmodium falciparum genomes from 26 sentinel sites across Uganda in 2023 and compared them with publicly available genomes from five neighboring countries. Genetic diversity was high and differentiation low in Uganda, but identity-by-descent detected limited structure. This was most pronounced in the low-transmission southwest, where parasites shared ancestry and recent relatedness with isolates from western Tanzania. Selection scans identified signals at loci associated with resistance to artemisinins and their partner drugs, and to chloroquine and antifolates. The strongest signal was at PfPX1 where the PIN haplotype (L1222P, M1701I, D1705N) reached 70% prevalence nationwide, but selection was carried by PIN haplotypes that had additionally acquired D384A, largely confined to northern and eastern Uganda. A second substitution at the same codon, D384Y, formed a haplotype shared across the Tanzanian border. PfKelch13 variants were partitioned across multiple backgrounds, consistent with repeated independent emergence, and C469Y was enriched on the PfPX1 D384A-PIN background. These genomes provide a 2023 baseline for tracking potential mediators of drug resistance and support coordinated genomic surveillance across Uganda and its neighbors.


  • Open Access

    PfPHAST: Plasmodium falciparum Public Health Amplicon Sequencing Tool, a Streamlined Panel for Malaria Genomic Surveillance

    by Francis D. Semakuba, Bienvenu Nsengimaana, Monica Mbabazi, Thomas Katairo, Kathryn Murie, Nicholas Hathaway, Innocent Wiringilimaana, John Vester Muwanika, Kore Lum, Milya Davlieva, et al.

    Genomic tools can support malaria control policy through surveillance of Plasmodium falciparum populations, tracking antimalarial drug resistance, pfhrp2/3 deletions that compromise rapid diagnostic tests, and selection at the circumsporozoite protein (PfCSP) vaccine target, as well as through molecular correction of therapeutic efficacy studies (TES). Multiplex Amplicons for Drug, Diagnostic, Diversity, and Differentiation Haplotypes using Targeted Resequencing (MAD 4 HatTeR), a comprehensive amplicon sequencing panel covering up to 276 targets, supports these applications but is tailored to research rather than routine programmatic use. We developed P. falciparum Public Health Amplicon Sequencing Tool (PfPHAST), a 56-target derivative of MAD 4 HatTeR spanning drug resistance loci, pfhrp2 / 3 deletion, PfCSP genotyping, non-falciparum species identification, and 20 high-heterozygosity microhaplotype loci for TES classification. We compared PfPHAST and MAD 4 HatTeR using laboratory strain controls, including two-strain dilution series and a five-strain mixture, across parasite densities of 100 to 10,000 parasites/µL. At matched per-target depth, PfPHAST achieved a higher quality-control pass rate than MAD4HatTeR (94.4% versus 90.0%) and distributed reads more evenly across targets. The panels showed comparable recall and precision for drug resistance codons and microhaplotypes, reaching near-complete recall above 40% within-sample allele frequency (WSAF) at all densities, with reduced sensitivity for minor alleles below 10% WSAF at low parasite density in both panels. Observed and expected WSAF correlated strongly for both panels, and both resolved a five-strain polyclonal mixture, including a 5% minor strain. By concentrating sequencing capacity on targets of greatest programmatic relevance, PfPHAST offers a scalable, lower-cost alternative to comprehensive research panels without sacrificing performance on shared targets, complementing MAD 4 HatTeR for routine molecular malaria surveillance.

  • Open Access

    Multiple local PfDHFR I164L haplotype expansions drive Plasmodium falciparum antifolate resistance in Uganda

    by Victor Asua, Karamoko Niaré, Shreeya Garg, Jenny Legac, Stephen Tukwasibwe, Thomas Katairo, Francis E. Bohissou, Rebecca M. Crudale, Alfred Simkin, Jerry Mulondo, et al.

    Mutations in the Plasmodium falciparum genes, pfdhfr and pfdhps , drive antifolate resistance and threaten malaria control in regions where sulfadoxine-pyrimethamine (SP) is the primary chemoprevention strategy. The spatial patterns and evolutionary dynamics of these mutations in high-transmission settings remain incompletely understood. Here we genotyped 11 resistance-associated mutations in pfdhfr and pfdhps in 4,725 P. falciparum isolates collected from 16 Ugandan health facilities as part of annual surveillance between 2016 and 2022. Notably, we show that the frequency of PfDHFR I164L, which confers higher pyrimethamine resistance, increased over time from 19.4% to 32.4%. Using identity-by-descent, haplotype structure, and extended haplotype homozygosity analyses, we show that PfDHFR I164L is present on multiple haplotype backgrounds and undergoes localised expansions, without detectable signatures of recent positive selection at all but one site. Our results suggest that the evolution of antifolate resistance, driven by PfDHFR I164L, is spatially heterogeneous and complex in regions that primarily use SP chemoprevention programmes.


  • Open Access

    Emergence and spread of Plasmodium falciparum PX1 polymorphisms associated with decreased susceptibility to antimalarials in Uganda

    by Karamoko Niaré, Bersabeh Tafesse, Mayland Treat, Jacob M. Sadler, Martin Okitwi, Stephen Orena, Victor Asua, Oriana Kreutzfeld, Jenny Legac, Jacob Marglous, et al.


  • Open Access

    Slowing the spread of treatment failure to artemisinin-based combination therapies in Uganda

    by Tran Dang Nguyen, Robert J. Zupko, Melissa D. Conrad, Gerald B. Rukundo, Carter C. Farinha, Victor D. Asua, Kien Trung Tran, Deborah M. Grace, Philip J. Rosenthal, Bosco B. Agaba, et al.

    The continuing spread of partially artemisinin-resistant Plasmodium falciparum in Africa is a health challenge that requires urgent attention. The World Health Organization has recommended multiple first-line therapies (MFT) as a response strategy. Implementing a response is critical for Uganda where four artemisinin resistance mutations are at local allele frequencies >0.20 and partner-drug efficacy may be at risk. Using a Uganda-calibrated individual-based mathematical model of P. falciparum transmission and evolution, we evaluate 53 public-sector deployment strategies for artemisinin-based combination therapies and report projected reductions in drug-resistance associated treatment failure from 2025 to 2031. Changing first-line therapy from artemether-lumefantrine (AL) to artesunate-amodiaquine (ASAQ) is projected to reduce treatment failures by 34.7% to 38.3% (90% range) while a first-line policy change to dihydroartemisinin-piperaquine (DHA-PPQ) is projected to reduce treatment failures by 10.0% to 12.9%. Optimal MFT deployments and cycling approaches balance their treatment distribution to higher ASAQ use and lower DHA-PPQ use, with projected treatment failure reduction at ~36% when compared to status quo AL use. Deployment of the triple therapy artemether-lumefantrine-amodiaquine is projected to reduce treatment failures by ~42% if enacted immediately. Increased adoption of and coverage with ASAQ is projected to play a large near-term role in reducing malaria treatment failure counts in Uganda.


  • Open Access

    Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024

    by Thomas Katairo, Victor Asua, Francis D. Semakuba, Bienvenu Nsengimaana, Shahiid Kiyaga, Nicholas Hathaway, Kathryn Murie, Stephen Tukwasibwe, Innocent Wiringilimaana, Jackie Nakasaanyaa, et al.

    The emergence and spread of drug resistance threaten malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Ten thousand thirty samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria and sequenced using the MAD 4 HatTeR panel and Illumina platforms; of these, 8,518 passed quality control and were analyzed. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y, and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.


  • Open Access

    The MARC SE-Africa dashboard: Joining forces to counteract emerging antimalarial resistance in South and East Africa

    by Stephanie van Wyk, Ishen Seocharan, Eulambius M. Mlugu, Dhol S. Ayuen, Donnie Mategula, Tikhala Makhaza, James Kiarie, Victor Asua, Jimmy Opigo, Aimable Mbituyumuremyi, et al.

    Regions within eastern and southern Africa (SE-Africa) carry some of the highest malaria burdens. Understanding the spatiotemporal dynamics of the emergence and spread of artemisinin (partial) resistance (ART-R) and how to mitigate ART-R is therefore of paramount importance in these areas. Here, we present a dashboard developed by the Mitigating Antimalarial Resistance Consortium for SE-Africa in collaboration with nineteen national control malaria programs (NCMPs) and their partners. The dashboard supports NCMPs’ decision-making by providing curated information on the latest available antimalarial resistance data. We systematically reviewed, collated, and visualized antimalarial resistance information from therapeutic efficacy studies, molecular surveillance for Pfkelch13 ART-R genetic markers, current in-country malaria treatment policies, and reported malaria cases and deaths. We identified evidence gaps in therapeutic efficacy and molecular surveillance, particularly in southern Africa. Five countries, Angola, the Democratic Republic of Congo, Kenya, Tanzania and Uganda, reported artemether-lumefantrine treatment failures above the WHO threshold of 10% after correcting for reinfections. The A675V, R561H, P574L, and C469F Pfkelch13 markers were highly prevalent in cross-border regions of several East African countries, with the C469Y marker rapidly spreading across Uganda. The dashboard provides an interactive platform for sharing regional data. We discuss the implications of these findings for policy, practice, and research.


  • Top Cited Papers
    Open Access

    Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24

    by Thomas Katairo, Victor Asua, Francis D. Semakuba, Bienvenu Nsengimaana, Shahiid Kiyaga, Nicholas Hathaway, Kathryn Murie, Stephen Tukwasibwe, Innocent Wiringilimaana, Jackie Nakasaanya, et al.

    The emergence and spread of drug resistance threatens malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria, sequenced using the MAD 4 HatTeR panel and Illumina platforms. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.


  • Open Access

    The MARC SE-Africa Dashboard: Joining Forces to Counteract Emerging Antimalarial Resistance in South and East Africa

    by Stephanie van Wyk, Ishen Seocharan, Eulambius M. Mlugu, Dhol S. Ayuen, Donnie Mategula, Tikhala Makhaza, James Kiarie, Victor Asua, Jimmy Opigo, Aimable Mbituyumuremyi, et al.

    Regions within eastern and southern Africa (SE-Africa) carry some of the highest malaria burdens. Understanding the spatiotemporal changes in the emergence and spread of artemisinin (partial) resistance (ART-R) and how to mitigate ART-R is therefore of paramount importance in these areas. Here, we present a dashboard developed by the Mitigating Antimalarial Resistance Consortium for SE-Africa in collaboration with nineteen national control malaria programs (NCMPs) and their partners. The dashboard supports NCMPs’ decision-making by providing curated information on the latest antimalarial resistance data available. We systematically reviewed, collated, and visualized antimalarial resistance information from therapeutic efficacy studies, molecular surveillance for Pfkelch13 ART-R genetic markers, current in-country malaria treatment policies, and reported malaria cases and deaths. We identified evidence gaps in therapeutic efficacy and molecular surveillance, particularly in southern Africa. Five countries, Angola, the Democratic Republic of Congo, Kenya, Tanzania and Uganda, reported artemether-lumefantrine treatment failures above the WHO threshold of 10% after correcting for reinfections. The A675V, R561H, P574L, and C469F Pfkelch13 markers were highly prevalent in cross-border regions of several East African countries, with the C469Y marker rapidly spreading across Uganda. The dashboard provides an interactive platform for data sharing at a regional level. We discuss the implications of these findings for policy, practice, and research. Author Summary: We introduce the MARC SE-Africa Dashboard, an innovative tool developed at the request of national malaria control programs to enhance the management of malaria through data-driven insights into antimalarial drug resistance in Southern and Eastern Africa. This interactive dashboard compiles and visualizes data from multiple sources, offering an up-to-date overview of resistance patterns and treatment efficacy. With its interactive maps and user-defined parameters, the dashboard enables detailed multinational and cross-border analysis, which is invaluable for identifying and monitoring emerging hotspots of resistance. This allows health professionals, researchers, and policymakers to target interventions effectively and adapt strategies in response to the evolving landscape of malaria resistance. The information visualized on the dashboard includes updated information on molecular markers of resistance, therapeutic efficacy outcomes, and national treatment policies for 19 malaria-endemic countries. The dashboard aims to facilitate regional cooperation in malaria management, which proves essential for proactive combat against malaria in high-risk areas. We discuss the insights gained from the curated and collated data and the manner in which this data and dashboard can support national malaria control programs and researchers.